Day One Biopharmaceuticals, Inc. (DAWN)
NASDAQ: DAWN · Real-Time Price · USD
21.20
+8.42 (65.88%)
At close: Mar 6, 2026, 4:00 PM EST
21.16
-0.04 (-0.19%)
After-hours: Mar 6, 2026, 7:58 PM EST
DAWN Revenue
In the year 2025, Day One Biopharmaceuticals had annual revenue of $158.18M with 20.60% growth. Day One Biopharmaceuticals had revenue of $53.72M in the quarter ending December 31, 2025, with 83.92% growth.
Revenue (ttm)
$158.18M
Revenue Growth
+20.60%
P/S Ratio
13.84
Revenue / Employee
$888,663
Employees
178
Market Cap
2.19B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 158.18M | 27.02M | 20.60% |
| Dec 31, 2024 | 131.16M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Galapagos NV | 1.31B |
| Ultragenyx Pharmaceutical | 673.00M |
| Zai Lab | 460.16M |
| Adaptive Biotechnologies | 276.98M |
| Iovance Biotherapeutics | 263.50M |
| Mesoblast | 65.38M |
| Ascentage Pharma Group International | 54.52M |
| Ocular Therapeutix | 51.95M |
DAWN News
- 9 hours ago - SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Day One Biopharmaceuticals, Inc. (DAWN) - Newsfile Corp
- 11 hours ago - Is there any upside left in DAWN stock as it soars 65%? - Invezz
- 15 hours ago - Day One Shares Surge After $2.5B Servier Deal - Benzinga
- 16 hours ago - Servier to buy Day One Biopharmaceuticals for total equity value of $2.5 billion - Reuters
- 16 hours ago - Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio - GlobeNewsWire
- 1 day ago - Day One Biopharmaceuticals: 'Strong Buy,' Several 2026 Milestones In Play Plus OJEMDA Growth - Seeking Alpha
- 7 days ago - Day One Biopharmaceuticals: Commercial Performance With Catalysts Ahead - Seeking Alpha
- 9 days ago - Day One Biopharmaceuticals, Inc. (DAWN) Q4 2025 Earnings Call Transcript - Seeking Alpha